Supplementary Table 1 from Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers
Paolo Peterlongo(IFOM), Javier Benı́tez(Spanish National Cancer Research Centre), Logan C. Walker(Churchill Hospital), Rosalind A. Eeles(Royal Marsden NHS Foundation Trust), Alex Miron(Case Western Reserve University), Stefan Wilkening(German Cancer Research Center), Elizabeth J. van Rensburg(University of Pretoria), Banu Arun(The University of Texas Health Science Center at Houston), Wendy K. Chung(Oregon Health & Science University), Jenny Chang‐Claude(Universität Hamburg), Jan Lubiński(Tumour Institute of Tuscany), Thomas van Overeem Hansen(University of Copenhagen), Bent Ejlertsen, Ana-Teresa Maia(Cancer Research UK), Felicity Lose(QIMR Berghofer Medical Research Institute), Ana Osório(Spanish National Cancer Research Centre), Marco Montagna(Azienda Ospedale - Università Padova), Robert L. Nussbaum(National Institutes of Health), Yuan Chun Ding(University of Copenhagen), Anna Jakubowska(Pomeranian Medical University), Olufunmilayo I. Olopade(University of Chicago), Jacques Simard(Université Laval), Ramūnas Janavičius(Vilnius University), Susan L. Neuhausen(City of Hope), Susan M. Domchek(University City Science Center), Ute Hamann(German Cancer Research Center), Katherine L. Nathanson(Translational Therapeutics (United States)), Timothy R. Rebbeck(Dana-Farber Cancer Institute), Saundra S. Buys(University of Utah), Sandra Oršulić(Cedars-Sinai Medical Center), Anne‐Marie Gerdes(Copenhagen University Hospital), Laura Matricardi(Istituto Oncologico Veneto), Anja Rudolph(Institut für Qualität im Management (Germany)), Cristina Martínez-Bouzas(Hospital Clínico Universitario Lozano Blesa), Frederieke H. van der Baan(Dutch Cancer Society), Bowang Chen(German Cancer Research Center), Matti A. Rookus(The Netherlands Cancer Institute), Beth Y. Karlan(University of California, Los Angeles), Jenny Lester, Melissa C. Southey(The University of Melbourne), Rita K. Schmutzler(Weatherford College), Cecilia M. Dorfling(QIMR Berghofer Medical Research Institute), Kirsten B. Moysich(Roswell Park Comprehensive Cancer Center), Amanda B. Spurdle(QIMR Berghofer Medical Research Institute), Lars Jønson(Copenhagen University Hospital), Douglas F. Easton, Penny Soucy(University of Cambridge), E. Gómez(Maastricht University Medical Centre), David E. Goldgar(University of Utah), Marjanka K. Schmidt(University of Cambridge)
Cited by 0
Related Papers
Integrated genomic analyses of ovarian carcinoma
|Nature|2011|8.2k
Mortality Results from a Randomized Prostate-Cancer Screening Trial
|New England Journal of Medicine|2009|2.9k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k